EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Onabotulinum Toxin A (BoNT‐A) for Drooling in Children: A Systematic Review and Meta‐Analysis

Haresh Oad, Alix Maltezeanu, Sabrina D da Silva iD, Sam J Daniel iD

The Laryngoscope · 2024

DOI: 10.1002/lary.31277 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Laryngoscope, 2024. Verfasst von Haresh Oad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Sialorrhea, Botulinum Toxins, Type A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sialorrhea, also known as drooling, hypersalivation, or ptyalism, has a significant impact on the medical and psychosocial well‐being of children. Onabotulinum toxin A (BoNT‐A) is the most commonly used botulinum toxin worldwide for the treatment of sialorrhea in children.

Objectives

To conduct a comprehensive systematic review and meta‐analysis to assess the clinical efficacy and potential adverse effects of BoNT‐A as a treatment for drooling in children.

Methods

Cochrane, Embase, and Medline databases were systematically searched (up to May 2023). Out of 535 identified publications, 20 were found eligible for inclusion. A systematic review and meta‐analysis were performed to determine the efficacy of BoNT‐A treatment in children in reducing the frequency and severity of drooling.

Results

Out of the 20 studies included, a meta‐analysis was conducted on the complete dataset of eight studies involving 131 patients. BoNT‐A was found to significantly decrease the severity of drooling in patients with sialorrhea (standardized mean difference [SMD], −2.07; 95% confidence interval [CI], −2.91 to −1.23; p < 0.0001) when compared with the conditions before injections using random‐effects models. Six studies out of 20 reported dysphagia as an adverse effect after injection. Other side effects included thickness of saliva and pain at the site of injection.

Conclusion

BoNT‐A is a clinically effective therapy that improves drooling severity in children with sialorrhea. Although there were some adverse side effects reported, they were transient and not severe. Future studies are needed to further evaluate the best techniques and to identify the ideal dosages required to achieve the optimal outcomes. Laryngoscope , 134:3012–3017, 2024

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SialorrheaBotulinum Toxins, Type AHumansChildNeuromuscular AgentsTreatment OutcomeChild, PreschoolAdolescentMaleFemale

Stichwörter der Autor:innen

BoNT‐Abotulinum neurotoxin‐Achildrendroolingsialorrhea

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.

ORCID-Profile: Sabrina D da Silva, Sam J Daniel

Zitieren

APA

Oad, H., Maltezeanu, A., da Silva, S. D., & Daniel, S. J. (2024). Onabotulinum Toxin A (BoNT‐A) for Drooling in Children: A Systematic Review and Meta‐Analysis. The Laryngoscope. https://doi.org/10.1002/lary.31277

Vancouver

Oad H, Maltezeanu A, da Silva SD, Daniel SJ. Onabotulinum Toxin A (BoNT‐A) for Drooling in Children: A Systematic Review and Meta‐Analysis. The Laryngoscope. 2024. doi:10.1002/lary.31277

BibTeX
@article{Oad2024,
  author = {Oad, Haresh and Maltezeanu, Alix and da Silva, Sabrina D and Daniel, Sam J},
  title = {Onabotulinum Toxin A (BoNT‐A) for Drooling in Children: A Systematic Review and Meta‐Analysis},
  journal = {The Laryngoscope},
  year = {2024},
  doi = {10.1002/lary.31277}
}
Kostenlos starten →